

This is a repository copy of *Letter to the Editor*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/id/eprint/96262/>

Version: Accepted Version

Article:

Sterrantino, Carmelo, Miroddi, Marco, Phillips, Bob orcid.org/0000-0002-4938-9673 et al. (1 more author) (2016) Letter to the Editor. *International Journal of Cancer*. pp. 2763-2770. ISSN: 1097-0215

<https://doi.org/10.1002/ijc.30005>

Reuse

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

Takedown

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing eprints@whiterose.ac.uk including the URL of the record and the reason for the withdrawal request.

Letter to the Editor

Carmelo Sterrantino, MD^{1,2}, Marco Miroddi, MD^{1,2}, Bob Phillips, MD, PhD^{2,3}, Lesley Stewart, PhD²

¹*Department of Clinical and Experimental Medicine, Policlinico "G. Martino", University of Messina, 98125 Messina, Italy*

²*Centre for Reviews and Dissemination, University of York, York, United Kingdom*

³*Department of Paediatric Oncology Haematology, Leeds General Infirmary, Leeds, United Kingdom*

Correspondence to: Carmelo Sterrantino, MD

Centre for Reviews and Dissemination, University of York, York YO10 5DD, UK; e-mail: helo.sterrantino@york.ac.uk, Tel: +44 (0)1904 321070 - Fax: +44 (0)1904 321041

Policlinico "G. Martino", University of Messina, Department of Clinical and Experimental Medicine, Via Consolare Valeria 5, 98125
– Messina, Italy; e-mail: csterrantino@unime.it, Tel: +39 090 2212697 - Fax: +39 090 2213300

This article has been accepted for publication and undergone full peer review but has not been through the copyediting, typesetting, pagination and proofreading process which may lead to differences between this version and the Version of Record. Please cite this article as an 'Accepted Article', doi: 10.1002/ijc.30005

Dear Editor,

We are writing to bring serious concerns about the validity of the paper ***“Hematologic toxicity assessment in solid tumor patients treated with cetuximab: A pooled analysis of 18 randomized controlled trials¹”*** authored by **Ran Cui and colleagues** recently published by the International Journal of Cancer to your attention. After careful reading, we firmly believe that the review uses inappropriate methods and incorrect data and therefore that the conclusions are misleading.

We should be clear that the reason that we have been able to consider the data so carefully is that our group is conducting a systematic review on serious thromboembolic adverse events which has a very similar design (PROSPERO registration number CRD42014009165²), although our systematic review also includes RCTs in which panitumumab (another approved anti-EGFR monoclonal antibody) is tested as an add-on to standard regimens.

We detail the many shortcomings of the research reported by Cui and colleagues below.

(1) Search strategy and missing trials

We were surprised by the small number of records (511) returned by the authors' initial search, the number of RCTS identified (18) and by the small number of articles that were excluded on grounds of lack of data (2). In contrast our own search, yielded a total of 6777 records of which 45^{3-5,7-48} were RCTs. Of the 37^{3-16,19-20,22-28,30-34,36-38,40-41,43,45,47-48} trials of cetuximab, 32^{3-6,8-12,14-16,19-20,22-28,30-34,36-38,40-41,43,45,47-48} reported data on hematologic toxicities.

Cui and colleagues do not report their search strategies in full, making it difficult to have confidence in their quality. From the information given, it would seem that, although there are several rigorous search filters that can be used to identify RCTs, none of these were used in either MEDLINE or Embase. It also seems that

the Cochrane Central Register of Controlled Trials was not used. The impact of these choices would be to restrict the number of papers identified by the literature searching.

As of October 31st, 2013, the time at which the literature search by Cui and colleagues was done, six of the additional sixteen RCTs that we identified were already published. These six trials (including over 1,700 participants) should therefore have been identified and added to the 18 trials they included (see Table 1).

To date, further data from more than 5,000 patients are available, as compared to the analysis of Cui and colleagues; around one third of these data were already published at the time of their search and therefore have been missed from the review.

(2) Inclusion of an ineligible trial

The authors included a trial reported by Cunningham et al.⁴⁹ in which both treatment and control groups received cetuximab. This does not match their stated inclusion criteria and should have been excluded from the review (for the same reason as they did exclude 3 trials - see flow-chart)¹.

(3) Quality assessment

The Authors assessed the quality of the evidence using the Jadad scale⁵⁰. The use of this scale is explicitly discouraged by Cochrane⁵¹. As well as suffering from the generic problems of scales, it has a strong emphasis on reporting rather than conduct, and does not cover one of the most important potential biases in randomized trials, namely allocation concealment. The PRISMA statement⁵², which Authors declare their paper to be compliant with, describes scales that numerically summarise multiple components into a single number as misleading

and unhelpful. In addition, the reported quality evaluation does not reflect the content of the articles reviewed. The Jadad Scale assigns up to two points out of a possible 5 score for blinding procedures⁵⁰. Although all the studies included in the analysis are open label, reducing the maximum score to 3 points, four studies received scores higher than 3^{5,10,31,49}.

(4) Inappropriate combination of neutropenia and leukopenia events

The authors have combined neutropenic events with broader leukopenic events (which include both neutropenia and lymphocytopenia) in the analyses. This is both inappropriate clinically, and unnecessary. In all the trials included in this study, neutropenia and leukopenia adverse events are listed separately, with the only exception being the trial reported by Ye and colleagues⁴⁷. Besides the clinical incoherence, potential double-counting and combination of overlapping outcomes may lead to analytical issues.

The issue of double counting is illustrated in the trial conducted by Lynch and colleagues²⁵, where the sum of neutropenic and leukopenic adverse events exceeds the denominator in the experimental arm. In their letter, Cui and colleagues responded to this by changing the denominator, but they did not provide any justification or description of the method used to calculate the new number.

Furthermore, summing leukopenic and neutropenic events is not applied consistently across trials. In at least one case only leukopenic events have been extracted and analysed¹². For the articles by Rosell and colleagues³⁴ it is not clear what has been done, as this trial, although listed in the summary table of included studies, does not appear in the forest plot of relative risk¹.

(5) Errors in data extraction/analysis

We found several inconsistencies between the data reported in the original articles and the data analysed in the review:

the analysis of wild type patients did not include the data presented by Bokemeyer⁵ and colleagues (see Figure 2 in the paper¹); while Cui and his group, reviewed the article published in 2009, the results were presented in a more recent report⁶, which was published by Annals of Oncology in 2011;

although data on neutropenia from the report by Rosell and colleagues³⁴ and data on anemia, from the EXPERT⁴⁵ trial reported by Vermorken et al. were presented in the articles reviewed, these trials do not appear in the analysis of relative risk (Figure 3¹ and Supporting information table s1 respectively); moreover data on anemia were available for the OPUS trial from the more recent report⁶ published in 2011;

in one case grade 4 adverse events were counted twice (Vermorken et al⁴⁵, see Table 2), while, in another, those of grade 3 were neglected (Rosell et al³⁴, see Table 3);

In at least one case, the proportion of adverse events, expressed as a percentage, was used as the actual number of events, without being converted³⁷.

Hematologic toxicities are one of the main concerns in patients exposed to cancer treatments. Considering the relevance of synthesized evidence in clinical practice as well as in regulatory decision-making processes, we strongly believe that the publication of misleading analyses, based on poor methods and incorrect data, in an important journal may have important consequences on public health and future research.

We believe that the extent of the errors in the Cui et al. article are substantial and that it may affect not only the estimates but even the direction of the effect. Readers of the journal and article need to be made aware of its potential to mislead.

Table 1. Published RCTs of anti-EGFR monoclonal antibodies

Author /Year (Study Name)	Trial phase	Underlying malignancy	Number randomized	Safety population	Treatment arm MoAbs	Treatment arm Controls	Anti-EGFr MoAbs	Follow up	Time-point of AEs assessment	Jadad score
Baselga 2013 (4)	2	Breastcancer	120 vs 61	114 vs 57	Cisplatin+ Cet	Cisplatin	Cet 400mg/m2; Cet 250mg/m2	NR	NR	3
BMS099 (25)	3	NSCLC	338 vs 338	325 vs 320	Cet+Taxane+carb	Taxane+ Carboplatin	Cet 400mg/m2; Cet 250mg/m2	NR	NR	3
Butts 2007 (10)	2	NSCLC	65 vs 66	64 vs 66	Gemcitabine + Cispatin (or Carboplatin) + Cet	Gemcitabine + Cispatin (or Carboplatin)	Cet 400mg/m2; Cet 250mg/m2	NR	30d ALDR	3
CALG B (16)	2	NSCLC	53 vs 48	53 vs 50	Pemetrexed + Carboplatin + Radiother + Cetuximab	Pemetrexed + Carboplatin + Radiother	Cet 400mg/m2; Cet 250mg/m2	32 months (11.7- 48.4)	Unclear	2
Cascinu 2009 (11)	2	Pancreatic cancer	42 vs 42	42 vs 42	Gemcitabine + Cispatin + Cet	Gemcitabine + Cispatin	Cet 400mg/m2; Cet 250mg/m2	11.8 months (2.5- 18.5)	NR	3
COIN (26)	3	mCRC	815 vs 815	815 vs 815	Fluorouracil or Capecitabine + Cet	Fluorouracil or Capecitabine	Cet400mg/m2; Cet250mg/m2	23 vs 21 months	NR	3
CRYSTAL (42)	3	mCRC	1217	600 vs 602	FOLFIRI + Cet	FOLFIRI	Cet 400mg/m2; Cet 250mg/m2	29.9 vs 29.4 months	NR	2
EXTREME (45)	3	SCHNC	222 vs 220	219 vs 215	Platinum + Fluorouracile + Cet	Platinum Fluorouracile	Cet 400mg/m2; Cet 250mg/m2	12.9 – 26.0 months	NR	3
FLEX (31)	3	NSCLC	557 vs 568	548 vs 562	Cisplatin + Vinorelbine + Cet	Cisplatin + Vinorelbine	Cet 400mg/m2; Cet 250mg/m2	23.8 months	Unclear	3
NCCTG N0147 (Alberts) (3)	3	Colorectal Cancer	954 vs 909 40 vs 106	894 vs 931 40 vs 106	mFOLFOX6 + Cet	mFOLFOX6	Cet 400mg/m2; Cet 250mg/m2	28 (0-68)	NR	2
Lorenzen 2009 (24)	2	Esophagus carcinoma	33 vs 33	32 vs 30	Cisplatin + 5- Fluorouracil + Cet	Cisplatin + 5- Fluorouracil	Cet 400mg/m2; Cet 250mg/m2	22.4 vs 21.0 months	30d ALDR	2
OPUS trial (6)	2	mCRC	169 vs 168	170 vs 168	Cet+FOLFOX4	Cet+FOLFOX4	Cet 400mg/m2; Cet 250mg/m2	NR	30d ALDR	2
Rosell 2008 (34)	2	NSCLC	43 vs 43	42 vs 43	Cisplatin + Vinorelbine + Cet	Cisplatin + Vinorelbine	Cet 400mg/m2; Cet 250mg/m2	NR	NR	3
S0205 trial (30)	3	Pancreatic cancer	372 vs 371	361 vs 355	Cet + Gemcitabine	Gemcitabine	Cet 400mg/m2; Cet 250mg/m2	NR	12 weeks AFA	2
SCOPE-1 (12)	2/3	Esophageal carcinoma	129 vs 129	129 vs 129	Cet+CRT	CRT	Cet 400mg/m2; Cet 250mg/m2	16.8 months	12w AFA	3
Siena 2010 (36)	2	mCRC	21 vs 21	21 vs 21	Cet+Lenalidomide	Lenalidomide	Cet 400mg/m2; Cet 250mg/m2	NR	28d ADLR	2
Sobrero 2008 (37)	3	mCRC	648 vs 650	638 vs 629	Cet + Irinotecan	Irinotecan	Cet 400mg/m2; Cet 250mg/m2	14.0 weeks	6w ALDR	2
Ye 2013 (47)	3	mCRC	70 vs 68	70 vs 68	Cet+ mFOLFOX6 (or FOLFIRI)	mFOLFOX6 (or FOLFIRI)	Cet 400mg/m2; Cet 250mg/m2	37 months	NR	2
Borner 2008 (8)	2	mCRC	37 vs 37	37 vs 37	XELOX + Cet	XELOX	Cet 400mg/m2; Cet 250mg/m2	17.2 months	NR	2
Burtness 2006 (9)	3	SCHNC	57 vs 60	58 vs 58	Cisplatin + Cetuximab	Cisplatin	Cet 200mg/m2; Cet 125mg/m2	NR	NR	2
EXPAND (23)	3	Gastric cancer	445 vs 449	446 vs 436	Capecitabine + Cisplatin + Cet	Capecitabine + Cisplatin	Cet 400mg/m2; Cet 250mg/m2	24.4 vs 21.0 months	30d ALDR	3
Fleming 2012 (35)	2	Prostate cancer	75 vs 40	75 vs 39	Cetuximab + Mitoxantrone	Mitoxantrone	Cet 400mg/m2; Cet 250mg/m2	NR	NR	2
NORDIC VII (40)	3	mCRC	194 vs 185	194 vs 185	FLOX + Cet	FLOX	Cet 400mg/m2; Cet 250mg/m2	NR	NR	2
Richards 2013 (33)	2	Gastroesophagealcanc er	75 vs 75	72 vs 68	Docetaxel + Oxaliplatin + Cet	Docetaxel + Oxaliplatin	Cet 400mg/m2; Cet 250mg/m2	NR	NR	2
Hussain 2014 (20)	2	Urothelial Carcinoma	60 vs 29	59 vs 28	Gemcitabine + Cisplatin + Cet	Gemcitabine + Cisplatin	500 mg/m2, days 1 and 15	NR	NR	2
Kim 2013 (22)	3	NSCLC	468 vs 470	451 vs 448	Docetaxel or pemetrexed + Cet	Docetaxel or pemetrexed	Cet 400mg/m2; Cet 250mg/m2	NR	NR	3
FOCUS3 (28)	2	Advanced CRC	47 vs 82	47 vs 82	Cet + FOLFIRI	FOLFIRI	Cet 500mg/m2 (bolus)	15.2 months (IQR 1/4 12.6-18.8)	NR	3
NCCTG N0147 (Huang) (19)	3	Colorectal cancer	40 vs 106	40 vs 106	FOLFIRI + Cet	FOLFIRI	Cet 400mg/m2; Cet 250mg/m2	28 months	NR	2
Malka 2014 (BINGO) (26)	2	Biliary tract cancer	76 vs 74	76 vs 68	Gemcitabine + Oxaliplatin + Cet	Gemcitabine + Oxaliplatin +	Cet 500mg/m2 biweekly	23 weeks (4–83)	NR	3
NEW EPOC (32)	2	mCRC	137 vs 134	137 vs 134	FU + OX + Cet or XELOX + Cet	FU + OX or XELOX	Cet 400mg/m2; Cet 250mg/m2	21.1 vs 19.8 months	NR	3
PETACC-8 (38)	3	Colorectal cancer	1,280 vs 1,279	1,149 vs 1,179	Cet+FOLFOX4	FOLFOX4	Cet 1,400mg/m2; Cet 250mg/m2	3.3 years (3.2–3.4)	30d ALDR	3
van den Heuvel 2014 (43)	2	NSCLC	51 vs 51	51 vs 51	Cet+Cis+RT	Cis+RT	Cet 400mg/m2; Cet 250mg/m2	29 months	12w AFA for AT; >12w for LT	2
Zhang 2014 (48)	NR	Advanced Urothelial Carcinoma	30 vs 26	30 vs 26	Cet + SOX	SOX	Cet 400mg/m2; Cet 250mg/m2	NR	NR	2
PACCE (17)	3b	mCRC	528 vs 525	407 vs 397	Pan+Bev-Ox/IRI	Bev-Ox/IRI	Pan 6 mg/kg	12.3/9.0 months	30d ALDR	2
Peeters 2010 (29)	3	mCRC	591 vs 595	541 vs 542	Pan+FOLFIRI	FOLFIRI	Pan 6 mg/kg	13.3 vs 10.2 months	30d ALDR	2
PICCOLO (35)	3	Colorectal cancer	230 vs 230	223 vs 224	Irinotecan + Pan	Irinotecan	Pan 9 mg/kg /3 weeks	NR	NR	3
PRIME (34)	3	mCRC	593 vs 590	539 vs 545	Pan+FOLFOX4	FOLFOX4	Pan 6 mg/kg	13.2 vs 12.5 months	30d ALDR	3
SPECTRUM (46)	3	SCHNC	327 vs 330	325 vs 325	Pan+Cis+FU	Cis+FU	Pan 9 mg/kg 3 weeks	44.0 vs 35.0 weeks	30d ADLR	3

Included

Missed

Published After October 31st 2013

Panitumumab

NR: Not Reported; NSCLC: Non Small Cell Lung Cancer; SCHNC: squamous cell head and neck cancer; mCRC: metastatic colorectal cancer; ALDR: After Last Dose Received; d: days;

w: weeks; AFA: After First Administration; AT: Acute toxicity; LT: Late Toxicity

John Wiley & Sons, Inc.

This article is protected by copyright. All rights reserved.

Table 2. Neutropenia and Leukopenia AEs in the RCTs included by Cui et al. as reported in the original articles.

Study ID	Leukopenia AEs as reported in RCTs				Neutropenia AEs as reported in RCTs				Neutropenia AEs in Cui et al.			
	Cetuximab Arm		Control Arm		Cetuximab Arm		Control Arm		Cetuximab Arm		Control Arm	
	Events	Total Pts	Events	Total Pts	Events	Total Pts	Events	Total Pts	Events	Total Pts	Events	Total Pts
Alberts (3)					156	1273	132	1261	156	1273	132	1261
Baselga (4)					11	114	3	57	11	114	3	57
Bokemeyer* (5,6)	12	170	10	168	51	170	57	168	63	170	67	168
Butts (10)					31	64	32	66	31	64	32	66
Cascinu (11)					10	42	6	42	10	42	6	42
Crosby (12)	14	129	21	129	15	129	24	129	14	129	21	129
Govindan (16)					25	53	21	50	25	53	21	50
Lorenzen (24)					7	32	4	30	7	32	4	30
Lynch (25)	139	325	97	320	198	325	177	320	337	634	274	632
Maughan (27)					101	815	107	815	101	815	107	815
Philip (30)	40	361	50	355	84	361	85	355	124	361	135	355
Pirker (31)	139	548	109	562	289	548	289	562	428	548	398	562
Rosell* (34)	21	42	16	43	35	42	23	43				
Sobrero (37)					196	617	151	595	196	638	151	629
Van Cutsem (41)	43	600	32	602	169	600	150	602	212	600	182	602
Vermorken (45)	19	219	19	215	49	219	50	215	81	219	92	215
Ye^ (47)					8	70	6	68	8	70	6	68
Cunningham§ (49)	Cetuximab		Cetuximab		20	212	0	115	20	212	0	115

*2009 instead of 2011 (no data on anemia)
*does not appear in any forest plot
^Ye et al. reported neutropenia/Leukopenia as one outcome
§ineligible
Leukopenia only
Unclear
safety population instead of actually tested
grade 3/4 + grade 4

Table 3. Anemia AEs in the RCTs included by Ran Cui et al. as reported in the original articles and main mistakes in data extraction

Study ID	Anemia AEs as reported in RCTs				Anemia AEs in Ran Cui et al.			
	Cetuximab Arm		Control Arm		Cetuximab Arm		Control Arm	
	Events	Total Pts	Events	Total Pts	Events	Total Pts	Events	Total Pts
Bokemeyer* (5,6)	7	170	4	168				
Butts (10)	17	64	13	66	17	64	13	66
Cascinu (11)	0	42	3	42	0	42	3	42
Crosby (12)	3	129	3	129	3	129	3	129
Govindan (16)	7	53	9	50	7	53	9	50
Lorenzen (24)	2	32	0	30	2	32	0	30
Lynch (25)	17	325	15	320	17	325	15	320
Maughan (27)	38	815	13	815	38	815	13	815
Philip (30)	35	361	22	355	35	361	22	355
Pirker (31)	76	548	94	562	76	548	94	562
Rosell (34)	6	42	6	43	0	42	1	43
Sobrero (37)	16	618	19	596	16	638	19	629
Vermorken* (45)	29	219	41	215				
Cunningham* (49)	Cetuximab		Cetuximab		10	212	3	115

*not found in forest plots

*Ineligible

grade 4 only (not converted from %)

safety population instead of actually tested

Reference List

1. Cui R, Chu L, Liu ZQ et al. Hematologic toxicity assessment in solid tumor patients treated with cetuximab: A pooled analysis of 18 randomized controlled trials. *Int J Cancer* 2014.
2. Miroddi M, Phillips R, Simmonds M, et al. Risk of severe (Grade 3-4) vascular thromboembolic adverse events related to anti-EGFR monoclonal antibodies (cetuximab and panitumumab) regimens administered in solid tumours: a meta-analysis of randomized controlled clinical trials. PROSPERO 2014:CRD42014009165 Available from http://www.crd.york.ac.uk/PROSPERO/display_record.asp?ID=CRD42014009165
3. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. *JAMA* 1383–93.
4. Baselga J, Gomez P, Greil R, et al. Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer. *J Clin Oncol* 2013;31:2586–92.
5. Bokemeyer C, Bondarenko I, Makhson A, et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. *J Clin Oncol* 2009;27:663–71.
6. Bokemeyer C, Bondarenko I, Hartmann JT et al. Efficacy according to biomarker status of cetuximab plus FOLFOX-4 as first-line treatment for metastatic colorectal cancer: the OPUS study. *Ann Oncol* 2011; 22: 1535-1546.
7. Bonner JA, Salter MM, Keene KS. Is cetuximab active in patients with cisplatin-refractory squamous cell carcinoma of the head and neck? *Nature Clinical Practice Oncology* 2007;4:690-91.
8. Borner M, Koeberle D, Von Moos R, et al.; Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland. Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK. *Ann Oncol*. 2008 Jul;19(7):1288-92. doi: 10.1093/annonc/mdn058. Epub 2008 Mar 17. PubMed PMID: 18349029.
9. Burtneß B, Goldwasser MA, Flood W et al. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. *J Clin Oncol* 2005; 23: 8646-8654.
10. Butts CA, Bodkin D, Middleman EL, et al. Randomized phase II study of gemcitabine plus cisplatin or carboplatin [corrected], with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. *J Clin Oncol* 2007;25:5777–84.
11. Cascinu S, Berardi R, Labianca R, et al. Cetuximab plus gemcitabine and cisplatin compared with gemcitabine and cisplatin alone in patients with advanced pancreatic cancer: a randomised, multicentre, phase II trial. *Lancet Oncol* 2008;9:39–44.

12. Crosby T, Hurt CN, Falk S, et al. Chemoradiotherapy with or without cetuximab in patients with oesophageal cancer (SCOPE1): a multicentre, phase 2/3 randomised trial. *Lancet Oncol* 2013;14:627–37.
13. Dewdney A, Cunningham D, Tabernero J, Capdevila J, Glimelius B, Cervantes A, Tait D, Brown G, Wotherspoon A, De Castro DG, Chua YJ, Wong R, et al. Multicenter randomized phase II clinical trial comparing neoadjuvant oxaliplatin, capecitabine, and preoperative radiotherapy with or without cetuximab followed by total mesorectal excision in patients with high-risk rectal cancer (EXPERT-C). *Journal of Clinical Oncology* 2012;30 (14):1620-27.
14. Douillard JY, Oliner KS, Siena S et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. *N Engl J Med* 2013; 369: 1023-1034.
15. Fleming MT, Sonpavde G, Kolodziej M et al. Association of rash with outcomes in a randomized phase II trial evaluating cetuximab in combination with mitoxantrone plus prednisone after docetaxel for metastatic castration-resistant prostate cancer. *Clin Genitourin Cancer* 2012; 10: 6-14.
16. Govindan R, Bogart J, Stinchcombe T, et al. Randomized phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unresectable non-small-cell lung cancer: Cancer and Leukemia Group B trial 30407. *J Clin Oncol* 2011; 29:3120–5.
17. Hecht JR, Mitchell E, Chidiac T et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. *J Clin Oncol* 2009; 27: 672-680.
18. Helbling D, Bodoky G, Gautschi O, Sun H, Bosman F, Gloor B, Burkhard R, Winterhalder R, Madlung A, Rauch D, Saletti P, Widmer L, et al. Neoadjuvant chemoradiotherapy with or without panitumumab in patients with wild-type KRAS, locally advanced rectal cancer (LARC): A randomized, multicenter, phase II trial SAKK 41/07. *Annals of Oncology* 2013;24 (3) (pp 718-725).
19. Huang J, Nair SG, Mahoney MR et al. Comparison of FOLFIRI With or Without Cetuximab in Patients With Resected Stage III Colon Cancer; NCCTG (Alliance) Intergroup Trial N0147. *Clinical colorectal cancer* 2014; 13: 100-109.
20. Hussain M, Daignault S, Agarwal N et al. A randomized phase 2 trial of gemcitabine/cisplatin with or without cetuximab in patients with advanced urothelial carcinoma. *Cancer* 2014; 120 (17): 2684-2693.
21. Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcborg JR, Tu D, Au H-J, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, et al. Cetuximab for the treatment of colorectal cancer. *New England journal of medicine* 2007;357:2040-8.
22. Kim ES, Neubauer M, Cohn A, Schwartzberg L, Garbo L, Caton J, Robert F, Reynolds C, Katz T, Chittoor S, Simms L, Saxman S. Docetaxel or pemetrexed with or without cetuximab in recurrent or progressive non-small-cell lung cancer after platinum-based therapy: a phase 3, open-label, randomised trial.[Erratum appears in *Lancet Oncol.* 2014 Jan;15(1):e4]. *Lancet oncology* 2013;14:1326-36.

23. Lordick F, Kang YK, Chung HC et al. Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. *Lancet Oncol* 2013; 14: 490-499.
24. Lorenzen S, Schuster T, Porschen R, et al. Cetuximab plus cisplatin-5-fluorouracil versus cisplatin-5-fluorouracil alone in first-line metastatic squamous cell carcinoma of the esophagus: a randomized phase II study of the Arbeitsgemeinschaft Internistische Onkologie. *Ann Oncol* 2009;20:1667-73.
25. Lynch TJ, Patel T, Dreisbach L, et al. Cetuximab and first-line taxane/carboplatin chemotherapy in advanced non-small-cell lung cancer: results of the randomized multicenter phase III trial BMS099. *J Clin Oncol* 2010;28:911-7.
26. Malka D, Cervera P, Foulon S et al. Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. *Lancet Oncol* 2014; 15: 819-828.
27. Maughan TS, Adams RA, Smith CG, et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. *Lancet* 2011;377:2103-14.
28. Maughan TS, Meade AM, Adams RA et al. A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine? *British journal of cancer* 2014; 110: 2178-2186.
29. Peeters M, Price TJ, Cervantes A et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. *J Clin Oncol* 2010; 28: 4706-4713.
30. Philip PA, Benedetti J, Corless CL, et al. Phase III study comparing gemcitabine plus cetuximab versus gemcitabine in patients with advanced pancreatic adenocarcinoma: Southwest Oncology Group-directed intergroup trial S0205. *J Clin Oncol* 2010;28:3605-10.
31. Pirker R, Pereira JR, Szczesna A, et al. Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial. *Lancet* 2009;373:1525-31.
32. Primrose J, Falk S, Finch-Jones M et al. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial. *Lancet Oncol* 2014; 15: 601-611.
33. Richards D, Kocs DM, Spira AI et al. Results of docetaxel plus oxaliplatin (DOCOX) +/- cetuximab in patients with metastatic gastric and/or gastroesophageal junction adenocarcinoma: results of a randomised Phase 2 study. *Eur J Cancer* 2013; 49: 2823-2831.
34. Rosell R, Robinet G, Szczesna A, et al. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-

expressing advanced non-small-cell lung cancer. *Ann Oncol* 2008;19:362–9.

35. Seymour MT, Brown SR, Middleton G et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. *Lancet Oncol* 2013; 14: 749-759.

36. Siena S, Cutsem E, Li M, Jungnelius U, Romano A, Beck R, Bencardino K, Elez ME, Prenen H, Sanchis M, Sartore-Bianchi A, Tejpar S, et al. Phase II open-label study to assess efficacy and safety of lenalidomide in combination with cetuximab in kras-mutant metastatic colorectal cancer *PloS one*, 2013.

37. Sobrero AF, Maurel J, Fehrenbacher L, et al. EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. *J Clin Oncol* 2008;26:2311–9.

38. Taieb J, Tabernero J, Mini E et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. *Lancet Oncol* 2014; 15: 862-873.

39. Tol J, Koopman M, Cats A, Rodenburg CJ, Creemers GJM, Schrama JG, Erdkamp FLG, Vos AH, Van Groenigen CJ, Sinnige HAM, Richel DJ, Voest EE, et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. *New England journal of medicine* 2009;360 (6):563-72.

40. Tveit K, Guren T, Glimelius B et al. Randomized phase III study of 5-fluorouracil/folate/oxaliplatin given continuously or intermittently with or without cetuximab, as first-line treatment of metastatic colorectal cancer: The NORDIC VII study (NCT00145314), by the Nordic Colorectal Cancer Biomodulation Group. *Journal of Clinical Oncology*. Conference 2011; 29.

41. Van Cutsem E, Kohne CH, Hitre E, et al. Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 2009;360:1408–17.

42. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer *Journal of clinical oncology*, 2007:1658-64.

43. van den Heuvel MM, Uytendinck W, Vincent AD et al. Additional weekly Cetuximab to concurrent chemoradiotherapy in locally advanced non-small cell lung carcinoma: efficacy and safety outcomes of a randomized, multi-center phase II study investigating. *Radiother Oncol* 2014; 110: 126-131.

44. Venook A, Niedzwiecki D, Hollis D, et al. Phase III study of irinotecan/5FU/LV (FOLFIRI) or oxaliplatin/5FU/LV (FOLFOX) {+/-} cetuximab for patients (pts) with untreated metastatic adenocarcinoma of the colon or rectum (MCRC): CALGB 80203 preliminary results *Journal of Clinical Oncology: ASCO annual meeting proceedings*, 2006:3509.

45. Vermorken JB, Mesia R, Rivera F, et al. Platinum-based chemotherapy plus cetuximab in head and neck cancer. *N Engl J Med* 2008;359:1116–27.

46. Vermorken JB, Stohlmacher-Williams J, Davidenko I et al. Cisplatin and fluorouracil with or without panitumumab in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck (SPECTRUM): an open-label phase 3 randomised trial. *Lancet Oncol* 2013; 14: 697-710.
47. Ye LC, Liu TS, Ren L, et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. *J Clin Oncol* 2013;31:1931-8.
48. Zhang ZD, Kong Y, Yang W et al. Clinical evaluation of cetuximab combined with an S-1 and oxaliplatin regimen for Chinese patients with advanced gastric cancer. *World journal of surgical oncology* 2014; 12 (1).
49. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. *N Engl J Med* 2004;351:337-45.
50. Clark HD, Wells GA, Huet C et al. Assessing the quality of randomized trials: reliability of the Jadad scale. *Control Clin Trials* 1999; 20: 448-452.
51. Higgins JPT, Green S (editors). *Cochrane Handbook for Systematic Reviews of Interventions* Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochrane-handbook.org.
52. Liberati A, Altman DG, Tetzlaff J et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. *BMJ* 2009; 339: b2700.